Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0TW3L
|
||||
| Former ID |
DIB010191
|
||||
| Drug Name |
CD20Bi aATC
|
||||
| Synonyms |
CD20Bi aATC; CD20Bi activated T-cells (non-Hodgkin's lymphoma), Wayne State University/Barbara Ann Karmanos Cancer Institute; CD20Bi-armed ATC (non-Hodgkin's lymphoma), Wayne State University/Barbara Ann Karmanos Cancer Institute; Anti-CD3/anti-CD20 bispecific antibody-armed activated T-cells (non-Hodgkin's lymphoma); Anti-CD3/anti-CD20 bispecific antibody-armed activated T-cells (non-Hodgkin's lymphoma), Wayne State University/Barbara Ann Karmanos Cancer Institute
|
||||
| Indication | Non-hodgkin's lymphoma [ICD10:C85] | Phase 1 | [1] | ||
| Company |
Barbara Ann Karmanos Cancer Institute
|
||||
| Target and Pathway | |||||
| Target(s) | T-cell surface glycoprotein CD3 | Target Info | Modulator | [1] | |
| B-lymphocyte antigen CD20 | Target Info | Modulator | [1] | ||
| KEGG Pathway | Hematopoietic cell lineage | ||||
| References | |||||
| REF 1 | CD20-Targeted T Cells after Stem Cell Transplantation for High Risk and Refractory Non-Hodgkin's Lymphoma. Biol Blood Marrow Transplant. 2013 June; 19(6): 925-933. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.